Phase 3 KEYNOTE-B15 data demonstrate that perioperative enfortumab vedotin and pembrolizumab significantly improve EFS, OS, and pCR compared with standard chemotherapy.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

Pfizer and Astellas have received the US Food and Drug Administration (FDA) acceptance for priority review of their ...

FDA grants Priority Review for Padcev plus Keytruda in muscle-invasive bladder cancer, showing improved survival and reduced ...

Stocks of cisplatin are now able to meet demand for the widely used chemotherapy drug that had been in short supply in the U.S. over the last year, the FDA's top official said. FDA Commissioner Robert ...

Patients with cancer who received prophylactic intravenous (IV) magnesium before starting cisplatin had a lower risk for cisplatin-associated acute kidney injury (AKI) than those who did not receive ...

Cisplatin and other platinum-based drugs are prescribed for 10% to 20% of all cancer patients, according to the National Cancer Institute. Cisplatin has a cure rate of over 90% when used to treat ...

Nimotuzumab combined with chemotherapy in the first-line treatment for patients with stage IVB, recurrent or persistent cervical squamous cell carcinoma: A multi ...

Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): An open-label, single-arm, phase 2 study. This is an ASCO Meeting Abstract from ...

For patients with locally advanced head and neck squamous cell carcinoma who cannot tolerate platinum chemotherapy, docetaxel is a sound alternative to enhance sensitivity to radiotherapy, say ...